CAD
RVNC

Craig A. Drill’s Revance Therapeutics, Inc. RVNC Stock Holding History

Craig A. Drill’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-65,600
Closed -$892K – 15
2016
Q2 		$892K Buy
+65,600
New +$1.16M 1.76% 12

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Craig A. Drill's RVNC Position: Q3 2016 in Review

Craig A. Drill sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2016, closing a stake of 65,600 shares — an estimated $892K sold.

Craig A. Drill first reported a position in RVNC in Q2 2016 and held it in 1 quarter. The position peaked at $892K in Q2 2016. 74 funds tracked by Wall St. Rank hold RVNC as of Q3 2016.

  • Craig A. Drill reported no remaining Revance Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
  • Craig A. Drill sold 65,600 Revance Therapeutics, Inc. shares in Q3 2016, an estimated $892K.
  • Craig A. Drill first reported a position in Revance Therapeutics, Inc. in Q2 2016 and held it in 1 quarter.
  • Craig A. Drill's Revance Therapeutics, Inc. position peaked at $892K in Q2 2016.
  • 74 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2016.

Based on Craig A. Drill's 13F filing for Q3 2016, filed 10 Nov 2016.